According to latest studies, a single dose of new antiviral drug Peramivir is safe and effective in treating influenza in adults when it is administered within 48 hours of the appearance of the symptoms of Flu.
Study researcher Richard Whitley, MD, distinguished professor of pediatrics and director of the division of pediatric infectious diseases at the University of Alabama at Birmingham School of Medicine, said in a press release, “Based on clinical data, peramivir is the first neuramindase inhibitor that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza. According to a retrospective combined analysis of two clinical studies, a single dose of peramivir, administered intramuscularly, alleviated flu symptoms, including fever, significantly faster than the studies’ placebo arms.”
Peramivir appears to be safe and effective in treating influenza symptoms, according to the results from clinical trials.
In 2 multicenter studies one phase 2 and one phase 3, 427 adults were administered a single IM injection of 300 mg of peramivir which is a product of BioCryst Pharma. The injection along with placebo was administered within 48 hours of the appearance of symptoms in acute uncomplicated influenza. Peramivir was capable of reducing the median time for flu-symptoms to alleviate by 22 hours. Researchers analyzed the data obtained from phase 2 and phase 3 placebo-controlled clinical trials and found that the drug was able to alleviate the flu symptoms if given within 48 hours of the appearance of the symptoms.
Researchers found that in comparison to placebo peramivir was able to alleviate the symptoms within 22 hours and reduce fever within 24 hours. The drug was also well tolerated.
Peramivir has been approved in Japan and Korea back in 2010. an estimated one million Japanese people have been treated with the drug. In the U.S., around 2,700 patients have received the drug in 27 clinical trials.